Duration of dual anti-platelet therapy – State of the art after the DAPT and PEGASUS-TIMI 54 trials. Issue 3 (4th May 2017)

• Record Type: Journal Article
• Authors: Pirlet, Charles; Legrand, Victor; Nyssen, Astrid; Pierard, Luc; Gach, Olivier
• Is Part Of: Acta cardiologica. Volume 72:Issue 3(2017)
• Page Start: 256
• Page End: 264
• Publication Date: 2017-05-04
• Subjects: Dual antiplatelet therapy -- bleeding -- stent thrombosis; Cardiology -- Periodicals; Cardiology; Cardiologie -- Périodiques; Cardiology; Cardiologie; Periodicals; Periodicals; 616.12005
• DOI: 10.1080/00015385.2017.1305189
• Languages: English
• ISSNs: 0001-5385

Abstract

Abstract: Dual anti-platelet therapy is prescribed in the setting of coronary heart disease for the prevention of stent thrombosis and acute thrombotic events. The optimal duration of dual anti-platelet therapy is still under debate as numerous trials have shown non-inferiority of a strategy of early cessation of one of the agents as compared to the standard practice whereas two larger trials have demonstrated benefit of prolonging dual anti-platelet therapy.